FY2026.Q2 consolidated results are in the vicinity of 1 trillion yen in net sales, with both operating income and net income down YoY, but overall showing a recovery trend. Among segments, the pharmaceutical dispensing system remains the core growth driver. The outlook moving forward is under review to identify factors that may affect the full-year forecast.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4820","jir_company_name":"\u682a\u5f0f\u4f1a\u793e EM\u30b7\u30b9\u30c6\u30e0\u30ba","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-10","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4820-20260810-01.pdf","jir_short_summary":"FY2026.Q2 consolidated results are in the vicinity of 1 trillion yen in net sales, with both operating income and net income down YoY, but overall showing a recovery trend. Among segments, the pharmaceutical dispensing system remains the core growth driver. The outlook moving forward is under review to identify factors that may affect the full-year forecast.","jir_summary":"### Section Heading\nThe earnings release explains the key points of FY2026.Q2 consolidated results, along with segment-specific\u72b6\u6cc1 and future outlook. Net sales declined YoY, while the company is re-evaluating the business structure and assessing the impact of new initiatives. It details the segment composition and main drivers, and discusses factors that exerted pressure on profits this period.\n\n### Section 2 Heading\nShareholder return policy and dividend direction are expected to continue in line with the current strategy. Key factors include profitability improvement in the dispensing system business, ARPU trends, and profitability of medical-related businesses. The outlook will continue to be assessed for alignment with the full-year plan.","jir_financial_highlights":"Net sales: FY2026 Q2 Actual 10,434 million yen (YoY \u25b314.1%)\nEBITDA: FY2026 Q2 Actual 1,371 million yen (YoY not indicated)\nOperating income: FY2026 Q2 Actual 922 million yen (YoY \u25b355.7%)\nNet income: FY2026 Q2 Actual 663 million yen (YoY \u25b358.6%)","jir_category":"","jir_hashtags":"#EMSystemsEarnings, Share buyback status, Shareholder returns policy, Segment-specific\u72b6\u6cc1, ARPU improvement initiatives","jir_key_figures":"FY2026 Q2 Net sales 10,434 million yen\nFY2026 Q2 Operating income 922 million yen\nFY2026 Q2 Net income 663 million yen","jir_meta_title":"\u3010EM Systems\u3011FY2026Q2 Earnings \u2014 Net sales 10,434 million yen, Operating income 922 million yen","jir_meta_description":"EM Systems FY2026Q2 earnings briefing. Key points on net sales and profit trends, segment\u72b6\u6cc1, future outlook, and shareholder return policy.","jir_og_title":"EM Systems FY2026Q2 Earnings \u2014 Net Sales 10,434 million yen","jir_og_description":"Consolidated results for FY2026Q2: net sales 10,434 million yen, operating income 922 million yen. Explaining segment\u72b6\u6cc1 and future outlook.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[]","ir_related_company":17294,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-101621","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n